Clinical validity of 25-gauge endobronchial ultrasound-guided transbronchial needle in lymph node staging of lung cancer

Yu Okubo¹²³, Yuji Matsumoto¹⁴, Midori Tanaka¹, Tatsuya Imabayashi¹, Yasuhito Uezono³⁵, Shun-ichi Watanabe², Takaaki Tsuchida¹

¹Department of Endoscopy, Respiratory Endoscopy Division, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan; ²Department of Thoracic Surgery, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan; ³Department of Comprehensive Oncology, Nagasaki University Graduate School of Biomedical Sciences, Tsukiji, Chuo-ku, Tokyo, Japan; ⁴Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan; ⁵Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo, Japan

Contributions: (I) Conception and design: Y Okubo, Y Matsumoto, M Tanaka, T Imabayashi, T Tsuchida; (II) Administrative support: Y Okubo, Y Matsumoto, M Tanaka, T Imabayashi, T Tsuchida; (III) Provision of study materials or patients: Y Okubo, Y Matsumoto, M Tanaka, T Imabayashi, T Tsuchida; (IV) Collection and assembly of data: Y Okubo, Y Matsumoto; (V) Data analysis and interpretation: Y Okubo, Y Matsumoto; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Yuji Matsumoto. Department of Endoscopy, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Email: yumatsum@ncc.go.jp.

Background: Endobronchial ultrasound-guided transbronchial needle aspiration is recommended for lymph node (LN) staging in lung cancer. Although 22-gauge needles are widely used, they may make some stations difficult to puncture owing to an acute angle. A thinner 25-gauge needle was introduced in Japan at the end of 2016 and offered structural advantages such as improved flexibility and penetrability. We aimed to validate the clinical utility of the 25-gauge needle in LN staging.

Methods: Patients who underwent endobronchial ultrasound-guided transbronchial needle aspiration for LN staging of lung cancer using the 25-gauge needle at our institution between November 2016 and March 2019 were included. Patient characteristics, staging procedures, pathology findings, and genetic testing success rates were assessed.

Results: Data of 130 patients were included in the analysis. The sampling rate was 87.6% (589/672 lesions). In addition to stations #4R, #7, and #11, which are generally easy to puncture, multiple stations (40.1%) were sampled. The diagnostic accuracy of combined computed tomography and fluorodeoxyglucose positron emission tomography was 82.3% and that of additional endobronchial ultrasound-guided transbronchial needle aspiration was 96.9%. The overall sensitivity, specificity, and positive and negative predictive values validated using resected specimens were 97.1% (34/35), 100% (41/41), 100% (34/34), and 97.6% (41/42), respectively. The success rate of genetic testing was 100% (34/34).

Conclusions: The new 25-gauge needle enabled us to approach a wide range of LNs with a desirable sampling rate and diagnostic accuracy in LN staging using endobronchial ultrasound-guided transbronchial needle aspiration, while providing enough tissue for genetic testing.

Keywords: Bronchoscopy; lung cancer; lymph nodes (LNs); staging; transbronchial needle aspiration

Submitted Nov 27, 2020. Accepted for publication Apr 02, 2021.
doi: 10.21037/jtd-20-3383
View this article at: http://dx.doi.org/10.21037/jtd-20-3383

^ ORCID: 0000-0003-4778-3762.
Introduction

Lung cancer is the leading cause of cancer incidence and mortality worldwide. Approximately 2.1 million new cases and 1.8 million deaths were reported in 2018, accounting for nearly 18.4% of all cancer-related deaths (1). The most important prognostic factor for lung cancer is disease stage, using the tumour-node-metastasis (TNM) classification of malignant tumours (2). Accurate staging can help reduce the rate of invasive procedures performed for patients unlikely to benefit from them and allows patients with curable disease to receive radical treatments, reducing the recurrence rate and improving the overall prognosis.

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a well-established procedure with a high diagnostic yield (3,4) and satisfactory safety profile (3,5); it is used in the differential diagnosis and lymph node (LN) staging of lung cancer (6). The other modalities recommended for staging are computed tomography (CT) and fluorodeoxyglucose positron emission tomography (FDG-PET); however, their diagnostic performance is insufficient, with a pooled sensitivity and specificity of CT estimated at 52–75% and 66–88% (7-10), respectively, and those of FDG-PET at 71–85% and 85–91% (11-14), respectively.

In contrast, EBUS-TBNA has a high diagnostic potential due to its capacity for making a pathological diagnosis with real-time guidance. In fact, the addition of EBUS-TBNA to the conventional combined CT and FDG-PET has been shown to improve diagnostic accuracy, with an estimated sensitivity and specificity of CT estimated at 52–75% and 66–88% (7-10), respectively, and those of FDG-PET at 71–85% and 85–91% (11-14), respectively.

In contrast, EBUS-TBNA has a high diagnostic potential due to its capacity for making a pathological diagnosis with real-time guidance. In fact, the addition of EBUS-TBNA to the conventional combined CT and FDG-PET has been shown to improve diagnostic accuracy, with an estimated sensitivity and specificity of CT estimated at 52–75% and 66–88% (7-10), respectively, and those of FDG-PET at 71–85% and 85–91% (11-14), respectively.

Methods

This was a retrospective cohort study that included patients who underwent EBUS-TBNA for LN staging at our institution between November 2016 and March 2019. Cases that involved staging of previously confirmed or suspected primary lung cancer were included. Patients with histologically confirmed benign disease or other malignancies, patients with stage IV disease confirmed by other modalities, and patients who underwent re-staging after initial therapy for lung cancer were excluded. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The in-house National Cancer Centre Institutional Review Board (No. 2018-090) approved the study and written consent for bronchoscopy was obtained from all participants.

Equipment and procedures

All procedures were performed with a convex probe-EBUS scope UC260FW (Olympus, Tokyo, Japan) and 25-G Expect™ Pulmonary Needle (Boston Scientific, MA, USA) by bronchoscopy experts or resident trainees under direct expert supervision. To make the patient comfortable during the procedure, moderate to deep sedation was maintained with a combination of intravenous narcotics (fentanyl or pethidine) and sedatives (propofol or midazolam). The bronchoscope was inserted via the oral route after topical aerosolised 8% lidocaine was applied; local intratracheal anaesthesia was performed with a 2% lidocaine injection.

Visual LN survey through EBUS-TBNA was performed in the order of N1, N2, and N3 stations. If the primary lesion was located along the central airway, it was assessed first. The risk of metastasis to each LN was systematically assessed with the following ultrasound modes. First, the B mode was used to assess the size, shape, margin, echogenicity, and the presence of a central hilar structure and a central necrosis sign (21). Second, the power/colour Doppler mode was used to assess the vascular patterns (22).
Third, elastography was used to assess the relative stiffness of tissue when available (23). These features were identified during real-time evaluation.

Subsequently, LNs with echoic findings suggestive of malignancy (15,21) or at a location important to treatment protocols (such as N>2), depending on their metastatic status, were punctured in the order of N3, to N2, to N1 stations. If an unconfirmed primary lesion was noted, it was sampled last to prevent contamination.

Once the target LN or primary lesion had been identified, a needle with a stylet was inserted in real time into the target LN. After the puncture was performed and the needle tip was inside the tissue, the stylet was inserted beyond the tip to push out bronchial cells and minimise contamination. The stylet was then removed. The target LN was subjected to 20–30 needle strokes, while negative pressure was applied using a syringe to obtain tissue samples. However, in case of significant sample contamination with blood, the slow-pull technique was applied instead. Prior to retracting the needle into the sheath, the suction was removed to minimise the sample loss into the syringe (if used). Finally, the needle was removed from the bronchoscope to process the sample.

The tissues present within the needle were air-flushed into a slide glass for histologic examination. The needle was then flushed with normal saline solution to prevent clogging. The fluid used through this flushing was also collected using specimen containers for cytological examination. Wherever possible, the procedure was repeated at least twice to ensure sample adequacy. Each operator, depending on the results of the rapid on-site evaluation (ROSE), made decisions regarding sampling termination or addition. Moreover, for some LNs that were difficult to approach transbronchially, endoscopic ultrasound with bronchoscope-guided fine needle aspiration was also used.

**Data collection and analysis**

Data on patient age, sex, primary lesion lobe, punctured lesion, size of target lesions or LNs, number of needle passes, sampling rate, complications, and staging and pathology findings were extracted from the database at our institution. The genetic testing success rate was assessed.

The size of target lesions or LNs was measured by the short axis on a CT scan. The sampling rate was calculated as the ratio of number of passes core tissues could receive to that of total passes. After staging, some genetic testing was performed for patients who were eligible for chemotherapy or chemo-radiotherapy. The genetic testing included single-gene testing for targetable driver oncogenes, such as epidermal growth factor receptor mutation using the Cobas® EGFR mutation test (Roche Molecular Systems, CA, USA), and anaplastic lymphoma kinase (split fluorescence in situ hybridization assays). The success rate of genetic testing was calculated as the ratio of the number of samples with enough tissue for genetic testing to that of all samples. In patients with malignant LNs, determination was based on the cytology results of EBUS-TBNA with a subsequent clinical course consistent with that of malignant disease or with surgical-pathologic confirmation. In patients with benign LNs, determination was based on surgical-pathologic confirmation by complete thoracic lymphadenectomy or results of clinical follow-up of at least 12 months, demonstrating a lack of clinical or radiologic evidence of disease progression. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated. The diagnostic accuracy with and without EBUS-TBNA was compared based on the results of the combined CT and FDG-PET. The staging results of patients who underwent surgery were verified using resected specimens. Descriptive statistics were reported as counts, frequencies (percentages), and medians (ranges).

**Results**

In total, 210 patients underwent EBUS-TBNA with the 25-G needle during the study period. Among them, 165 cases were eligible. Finally, the data of 130 patients were included in the analysis (shown in Figure 1).

Patient baseline characteristics and staging details are presented in Table 1. The median age was 69 [43–83] years, and most patients were male (71.5%). Most primary lesions were detected in the right lung (67.7%). A total of 349 lesions were sampled, and the median number of sampled locations per case was 3 [1–6]. The sampled locations varied with multiple stations (40.1%) in addition to stations #4R, #7, and #11, which were generally easy to puncture. The median size of the primary lesions was 23.1 (11.9–50.7) mm, while that of the LNs was 8.5 (3.2–40.8) mm.

The LN staging results are presented in Table 2. The median number of needle passes per lesion was 2 [1–4], and the sampling rate was 87.6% (589/672 lesions). All LN staging procedures were successfully performed without any severe complications. The most frequent histological
Type was adenocarcinoma (44.6%), followed by squamous cell carcinoma (25.4%), small cell carcinoma (17.7%), and other types (12.3%). Of the 58 adenocarcinomas, 34 cases eligible for chemotherapy or chemo-radiotherapy were submitted to genetic testing, and completed in all cases (success rate 100%). The comparison of clinical N stage (based on combined CT and FDG-PET and combined CT and FDG-PET plus EBUS-TBNA) between Final N stage based on pathological N stage of resected specimen, or clinical N stage based on results of clinical follow up, is shown in Table 3. The diagnostic accuracy of combined CT and FDG-PET was 82.3%, and that of additional EBUS-TBNA was 96.9%. EBUS-TBNA improved the diagnostic accuracy by 14.6%.

Finally, 40 cases (76 LNs) were pathologically verified using the specimens obtained during surgical resection (Table 4). The overall sensitivity, specificity, PPV, and NPV were 97.1% (34/35), 100% (41/41), 100% (34/34), and 97.6% (41/42), respectively.

Conclusions

This study validated the clinical utility of a 25-G needle in LN staging of lung cancer. To the best of our knowledge, this is the largest study on the clinical utility of EBUS-TBNA specifically for LN staging using the 25-G needle. The sampling rate and diagnostic yield obtained in this study were comparable to those obtained with traditional 22-G needles (3,4,6). However, a wide range of LNs, including those that were difficult to approach using 22-G needles (17,18), were aspirated using 25-G needles.

EBUS-TBNA is recommended for LN staging of lung cancer (6,15); however, the location of the tracheal or bronchial wall relative to target LNs can restrict needle access to these LNs. Although the combination of EBUS and EUS can help overcome this anatomical challenge (24-26), some LNs remain difficult to access, even by experts. This challenge is partially due to the structural limitations of standard 22-G needles. When 22-G needles...
Table 2 Results of lymph node staging

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Needle passes [median, range]</td>
<td>2 [1–4]</td>
</tr>
<tr>
<td>Sampling rate (%)</td>
<td>87.6</td>
</tr>
<tr>
<td>Severe complication</td>
<td>None</td>
</tr>
<tr>
<td>Histology, n (%)</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>58 (44.6)</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>33 (25.4)</td>
</tr>
<tr>
<td>Small cell carcinoma</td>
<td>23 (17.7)</td>
</tr>
<tr>
<td>Others</td>
<td>16 (12.3)</td>
</tr>
<tr>
<td>Success rate for molecular test</td>
<td>100</td>
</tr>
</tbody>
</table>

The sampling rate was calculated as the ratio of the number of passes core tissues could receive to that of total passes. The success rate of genetic testing was calculated as the ratio of the number of samples with enough tissue for genetic testing to that of all samples.

Table 3 Comparison of clinical N stage [the comparison of clinical N stage (based on combined CT and FDG-PET and combined CT and FDG-PET plus EBUS-TBNA) between Final N stage based on pathological N stage of resected specimen, or clinical N stage based on results of clinical follow-up is shown. Part (A) shows the comparison based on combined CT and FDG-PET, and part (B) shows the comparison based on combined CT and FDG-PET plus EBUS-TBNA]

<table>
<thead>
<tr>
<th>Variable</th>
<th>Final N stage</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Part A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical N stage based on CT and FDG-PET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>10*</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>17*</td>
</tr>
<tr>
<td>2</td>
<td>9</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>22</td>
<td>20</td>
</tr>
<tr>
<td>Part B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical N stage based on CT and FDG-PET plus EBUS-TBNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>22*</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>19*</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>22</td>
<td>20</td>
</tr>
</tbody>
</table>

The sum of the numbers with * where clinical N stage and final N stage matched was 107 for (A) combined CT and FDG-PET and 130 for (B) combined CT and FDG-PET plus EBUS-TBNA; the diagnostic accuracy of (A) and (B) were 82.3% (107/130) and 96.9% (126/130), respectively. Thus, EBUS-TBNA improved the diagnostic accuracy by 14.6%. CT, computed tomography; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; FDG-PET, fluorodeoxyglucose-positron emission tomography; N, nodal factor.

Table 4 Comparison of EBUS-TBNA and final diagnoses in surgical resected cases

<table>
<thead>
<tr>
<th>EBUS-TBNA results</th>
<th>Malignant</th>
<th>Benign</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignant</td>
<td>34</td>
<td>0</td>
<td>34</td>
</tr>
<tr>
<td>Benign</td>
<td>1</td>
<td>41</td>
<td>42</td>
</tr>
<tr>
<td>Total</td>
<td>35</td>
<td>41</td>
<td>76</td>
</tr>
</tbody>
</table>

The overall sensitivity, specificity, PPV, and NPV were 97.1% (34/35), 100% (41/41), 100% (34/34), and 97.6% (41/42), respectively. EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration.
with outer sheaths are inserted through the working channel of a bronchoscope, flexion of the tip is reduced due to the needles' rigidity. LNs requiring a needle tip to bend for them to be punctured (for example, #2, #3p, #4L, and #10, among others) cannot be fully visualised when the contact with the tracheal or bronchial wall is lost. Jhun et al. reported that the diagnostic sensitivity and NPV of left-sided LNs were lower than those of midline or right-sided LNs (17). Gafoor et al. reported that #2 LNs were difficult to access due to limited flexion of the bronchoscope when the needle was applied (18). However, these authors achieved EBUS-TBNA for #2R with the 25-G needle, after failure with the 22-G needle. They speculated that a smaller diameter (1.52 mm) and specific needle composition (cobalt chromium) accounted for the improved flexibility of the 25-G needle.

In this study, in addition to stations #4R, #7, and #11, which are generally easy to puncture using conventional 22-G needles, multiple stations (40.1%) were punctured using the 25-G needle, enabling us to approach a wide range of LNs, owing to the needle's flexibility. The 25-G needle has been used in EUS-FNA for abdominal lesions such as pancreatic masses before being introduced to EBUS-TBNA. The diagnostic yield and overall accuracy in EUS-FNA was comparable to those of the 22-G needle in a meta-analysis (19). Moreover, Camellini et al. reported that EUS-FNA was successfully performed using 25-G needles in masses at the uncinate process of the pancreas, which are difficult to puncture using the 22-G needle (27).

It was expected that needles as thin as 25-G may obtain smaller tissue samples and have a lower diagnostic yield than traditional 22-G needles. However, in this study, the sampling rate was 87.6%, and the diagnostic accuracy of the 25-G needle was 96.9% in all cases and 98.7% in surgically resected cases, suggesting a performance equivalent to that of 22-G needles (3,4,6). Furthermore, the LN staging revealed N2 and N3 stages in 54 and 32 cases, respectively; hence, 66.2% of the total cases showed progression, with mediastinal LN metastasis. Curative treatment such as surgery or radiation alone is not routinely recommended in these patients. Sufficient amounts of samples are needed for further genetic testing for an appropriate treatment choice (28).

In this study, there was enough tissue for genetic testing in all samples, yielding a success rate of 100%. Stov et al. reported that next generation sequencing succeeded in 100% of cytology smear samples, with EBUS-TBNA using 25-G needles (29). This finding might be due to improved penetrability and sharpness of 25-G needles compared to those of 22-G needles. These features enable such needles to puncture relatively hard structures such as bronchial cartilage and lesions with calcifications. It has been suggested that omitting the use of stylet during EBUS-TBNA did not affect diagnostic outcomes and reduce procedural complexity (30). However, as the 25-G needle could easily puncture bronchial cartilage, the stylet was inserted beyond the tip, pushing out bronchial epithelial cells and minimising contamination in this study.

Studies on the use of 25-G needles in EBUS-TBNA are limited. Di Felice et al. reported that 25-G and 22-G needles achieved comparable specimen adequacy and diagnostic accuracy in EBUS-TBNA; however, their data were not specific to LN staging (20). In this study, EBUS-TBNA performed alongside the conventional combination of CT and FDG-PET improved the diagnostic accuracy by 14.6%. The desirable diagnostic accuracy of EBUS-TBNA of 96.9%, compared with the accuracy found in previous studies, suggests its clinical usefulness in lung cancer staging (31).

In addition, although the frequency of complications of EBUS-TBNA using a 22-G needle is low (3,5), it is expected that the use of a 25-G needle will further reduce complications owing to its thinness (32). In the present study, no severe complications were observed, and we have had experience with EBUS-TBNA using a 25-G needle for diagnosis of hypervascular tumours such as metastatic lung tumour from renal cell carcinoma without any problems (33).

Despite its benefits, the use of the 25-G needle yielded some false negative findings in all cases (3.6%, 4/112) and surgically verified cases (2.9%, 1/35). Our study included a case, wherein an isolated tumour cell was confirmed in a resected specimen that was diagnosed as negative in preoperative EBUS-TBNA. Heterogeneous LNs that include both malignant and benign cells examined with several passes of EBUS-TBNA might yield false negative findings. However, it should be noted that the degree of sedation and number of needle passes were not prospectively standardised in this study; in fact, the degree of sedation might have been lighter, and the number of passes were lower than that recommended in early study stages (15). These factors might have affected our findings. Following standardisation, patients were kept under moderate to deep sedation and the number of needle passes was at least two, compliant with ROSE (34).

Another limitation of this study was that it was a single-centre retrospective study. Moreover, the performance of the 25-G needle was not directly compared with that of the 22-G needle, as this was a single-arm study. Owing
to the usefulness of the 25-gauge needle in staging in clinical practice, we have been performing all staging with the 25-gauge needle since its introduction; thus, it was impossible to make a comparison in the same period. A randomised controlled trial is required to confirm the utility of the 25-G needle and the 22-G needle.

In conclusion, the 25-G needle enabled us to approach a wide range of LNs, with a satisfactory sampling rate and diagnostic accuracy in LN staging of lung cancer with EBUS-TBNA.

Acknowledgments
The authors would like thank Dr Adrian Christopher Lu for his insightful comments and Editage (https://www.editage.jp/) for English language review. Funding: None.

Footnote
Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at http://dx.doi.org/10.21037/jtd-20-3383

Data Sharing Statement: Available at http://dx.doi.org/10.21037/jtd-20-3383

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-3383). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The in-house National Cancer Centre Institutional Review Board (No. 2018-090) approved the study and written consent for bronchoscopy was obtained from all participants.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


